Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EHMT1 | Q9H9B1 | 1/20 | 0.39 |
| ▸ | BCHE | P06276 | 1/20 | 0.38 |
| ▸ | AHCY | P23526 | 1/20 | 0.38 |
| ▸ | SLC29A1 | Q99808 | 1/20 | 0.37 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.36 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.35 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.34 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5498025 | 0.88 | EHMT1 (0.50) | EHMT1BCHEAHCYRXFP1ADORA2A | |
| SCHEMBL2955999 | 0.80 | BCHE (0.42) | BCHEAHCYADORA3ADORA2B | |
| SCHEMBL9687934 | 0.79 | SLC29A1 (0.43) | BCHEAHCYSLC29A1ADORA3ADORA2A | |
| SCHEMBL9223633 | 0.79 | DUT (0.48) | BCHEADORA3ADORA2AADORA2B | |
| SCHEMBL1140703 | 0.78 | EGFR (0.41) | BCHESLC29A1ADORA3ADORA2AADORA2B | |
| SCHEMBL13238881 | 0.78 | EGFR (0.41) | BCHESLC29A1ADORA3ADORA2AADORA2B | |
| SCHEMBL2045673 | 0.78 | EGFR (0.41) | BCHESLC29A1ADORA3ADORA2AADORA2B | |
| SCHEMBL9851825 | 0.78 | EHMT1 (0.44) | EHMT1BCHEAHCYSLC29A1RXFP1 | |
| SCHEMBL9851835 | 0.78 | EHMT1 (0.44) | EHMT1BCHEAHCYSLC29A1RXFP1 | |
| SCHEMBL2950104 | 0.77 | EGFR (0.40) | BCHESLC29A1ADORA3ADORA2AADORA2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1654270-B1 | PROCESS FOR PREPARING 2',3'-DIDEHYDRO-2',3'-DIDEOXYNUCLEOSIDES AND 2',3'-DIDEOXYNUCLEOSIDES | ARCHIMICA SRL (IT) | 2007-12-26 | — | — | EP | disclosed |
| US-20060199959-A1 | Process for preparing 2',3'-didehydro-2'3'-dideoxynucleosides and 2',3'-dideoxynucleosides | ARCHIMICA S.R.L. (IT) | 2006-09-07 | — | — | US | disclosed |
| EP-1654270-A1 | PROCESS FOR PREPARING 2',3'-DIDEHYDRO-2',3'-DIDEOXYNUCLEOSIDES AND 2',3'-DIDEOXYNUCLEOSIDES | Clariant Life Science Molecules (Italia) S.p.A. (IT) | 2006-05-10 | — | — | EP | disclosed |
| WO-2005012325-A1 | PROCESS FOR PREPARING 2',3'-DIDEHYDRO-2',3'-DIDEOXYNUCLEOSIDES AND 2',3'-DIDEOXYNUCLEOSIDES | CLARIANT LIFE SCIENCE MOLECULES (ITALIA) S.P.A. (IT) | 2005-02-10 | — | — | WO | disclosed |
| US-5466793-A | Catalytic reducing of a nucleoside with hydrogen in the presence of palladium and recovering | AJINOMOTO CO., INC. (JP) | 1995-11-14 | — | — | US | disclosed |
| US-5290927-A | Process for preparing 2',3'-dideoxyadenosine | AJINOMOTO CO., INC. (JP) | 1994-03-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060199959-A1 | Process for preparing 2',3'-didehydro-2'3'-dideoxynucleosides and 2',3'-dideoxynucleosides | DOHH, UMPS, DCPS | EHMT1 3758/4885BCHE 1098/4885AHCY 1343/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.